Lineage Cell Therapeutics (LCTX) EBIT Margin (2010 - 2026)

Lineage Cell Therapeutics has reported EBIT Margin for 17 years, with the latest figure at 440.17% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin fell 708.0% year-over-year to 440.17%; the trailing twelve-month figure through Mar 2026 stood at 104.1% (up 11900.0% YoY), and the FY2025 full-year result was 98.22%, up 12789.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 440.17%, down from 238.71% in the prior quarter.
• The five-year high for EBIT Margin was 238.71% in Q4 2025, with the low at 715.37% in Q2 2025.
• Historically, EBIT Margin has averaged 272.03% across 5 years, with a median of 278.37% in 2023.
• Annual changes were most pronounced in 2022 — EBIT Margin jumped 168094 bps — and 2023, when it sank 36297 bps.
• Lineage Cell Therapeutics' EBIT Margin stood at 346.68% in 2022, then grew by 12 bps to 304.69% in 2023, then surged by 42 bps to 178.17% in 2024, then soared by 234 bps to 238.71% in 2025, then slumped by 284 bps to 440.17% in 2026.
• The last three EBIT Margin figures came in at 440.17% (Q1 2026), 238.71% (Q4 2025), and 102.85% (Q3 2025), per Business Quant data.